Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden

Billie Pettersson, Mikael Hoffmann, David Andersson, Per Wändell and Lars-Åke Levin

Health Policy, 2012, vol. 108, issue 2, 207-215

Abstract: A new reimbursement scheme (RS) for glucose lowering therapies (GLT) was implemented in Sweden on March 1, 2010. Products on the market were retained, restricted, excluded or excluded for new courses in the new RS. The aim of this study was to compare utilization and costs of GLT for type 2 diabetes Mellitus (T2DM) before and after the implementation of the changed RS.

Keywords: Pricing and reimbursement policy; Glucose lowering therapies; Drug utilization; Health technology assessment; Health economics (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851012002898
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:108:y:2012:i:2:p:207-215

DOI: 10.1016/j.healthpol.2012.10.008

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().